Influenza A (H1N1) and the threat of pandemic

 
June 2009

Download our free disease briefing on influenza, and access further detailed sources of information.

As the influenza A (H1N1) virus spreads across the world, attention is focused on the pharmaceutical industry: how it will respond to the crisis, and what is being done to prevent further epidemics.

Thomson Reuters is adding its knowledge and expertise to the fight against this and further influenza A epidemics. We are pleased to offer, free to download by any interested party, our entire disease briefing on influenza, taken direct and unabridged from the wealth of information and knowledge in our investigational drug database Prous Science Integrity® and updated daily.

Download the free influenza A (H1N1) disease briefing

The disease briefings in Prous Science Integrity are dynamic executive summaries of the current status and future trends in drug therapy for a specific disease or disorder, providing key facts on the disease, such as risk factors, prevalence and incidence, morbidity and mortality figures, and cost, along with a structured, scientific approach to the R&D-related aspects of diagnosis, prevention and treatment. They utilize a mechanistic (target- or mechanism of action-based) approach to describing drug therapies that are currently under development and thus are potential new treatment options for the future.

The daily, free-to-download influenza disease briefing on the Thomson Reuters website differs from the information found on other H1N1 sites in its focus on drugs and vaccinations that are currently in the development pipeline or on the market. It brings a drug R&D approach to this subject, providing information designed for scientists in the pharmaceutical industry and academia, in contrast to the medical or epidemiological approaches found elsewhere.
It is our hope that making these data freely available will give investigators and researchers the information they need to better support efforts to limit its spread and severity.